1
|
Sacerdoti M, Gross LZF, Riley AM, Zehnder K, Ghode A, Klinke S, Anand GS, Paris K, Winkel A, Herbrand AK, Godage HY, Cozier GE, Süß E, Schulze JO, Pastor-Flores D, Bollini M, Cappellari MV, Svergun D, Gräwert MA, Aramendia PF, Leroux AE, Potter BVL, Camacho CJ, Biondi RM. Modulation of the substrate specificity of the kinase PDK1 by distinct conformations of the full-length protein. Sci Signal 2023; 16:eadd3184. [PMID: 37311034 DOI: 10.1126/scisignal.add3184] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 05/19/2023] [Indexed: 06/15/2023]
Abstract
The activation of at least 23 different mammalian kinases requires the phosphorylation of their hydrophobic motifs by the kinase PDK1. A linker connects the phosphoinositide-binding PH domain to the catalytic domain, which contains a docking site for substrates called the PIF pocket. Here, we used a chemical biology approach to show that PDK1 existed in equilibrium between at least three distinct conformations with differing substrate specificities. The inositol polyphosphate derivative HYG8 bound to the PH domain and disrupted PDK1 dimerization by stabilizing a monomeric conformation in which the PH domain associated with the catalytic domain and the PIF pocket was accessible. In the absence of lipids, HYG8 potently inhibited the phosphorylation of Akt (also termed PKB) but did not affect the intrinsic activity of PDK1 or the phosphorylation of SGK, which requires docking to the PIF pocket. In contrast, the small-molecule valsartan bound to the PIF pocket and stabilized a second distinct monomeric conformation. Our study reveals dynamic conformations of full-length PDK1 in which the location of the linker and the PH domain relative to the catalytic domain determines the selective phosphorylation of PDK1 substrates. The study further suggests new approaches for the design of drugs to selectively modulate signaling downstream of PDK1.
Collapse
Affiliation(s)
- Mariana Sacerdoti
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA)-CONICET-Partner Institute of the Max Planck Society, Buenos Aires C1425FQD, Argentina
| | - Lissy Z F Gross
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA)-CONICET-Partner Institute of the Max Planck Society, Buenos Aires C1425FQD, Argentina
| | - Andrew M Riley
- Medicinal Chemistry and Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK
| | - Karin Zehnder
- Department of Internal Medicine I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Abhijeet Ghode
- Biological Sciences, National University of Singapore, Singapore 119077, Singapore
| | - Sebastián Klinke
- Fundación Instituto Leloir, IIBBA-CONICET, and Plataforma Argentina de Biología Estructural y Metabolómica PLABEM, Buenos Aires C1405BWE, Argentina
| | - Ganesh Srinivasan Anand
- Biological Sciences, National University of Singapore, Singapore 119077, Singapore
- Department of Chemistry, Huck Institutes of the Life Sciences, Pennsylvania State University, 104 Chemistry Building, University Park, PA 16802, USA
| | - Kristina Paris
- Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA
- Department of Statistics, University of Pittsburgh, WWPH 1821, Pittsburgh, PA 15213, USA
| | - Angelika Winkel
- Department of Internal Medicine I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Amanda K Herbrand
- Department of Internal Medicine I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - H Yasmin Godage
- Wolfson Laboratory of Medicinal Chemistry, Department of Life Sciences, University of Bath, Claverton Down, Bath BA2 7AY, UK
| | - Gyles E Cozier
- Wolfson Laboratory of Medicinal Chemistry, Department of Life Sciences, University of Bath, Claverton Down, Bath BA2 7AY, UK
| | - Evelyn Süß
- Department of Internal Medicine I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Jörg O Schulze
- Department of Internal Medicine I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Daniel Pastor-Flores
- Department of Internal Medicine I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
- KBI Biopharma, Technologielaan 8, B-3001 Leuven, Belgium
| | - Mariela Bollini
- Centro de Investigaciones en Bionanociencias 'Elizabeth Jares-Erijman' CIBION, CONICET, Buenos Aires C1425FQD, Argentina
| | - María Victoria Cappellari
- Centro de Investigaciones en Bionanociencias 'Elizabeth Jares-Erijman' CIBION, CONICET, Buenos Aires C1425FQD, Argentina
| | - Dmitri Svergun
- European Molecular Biology Laboratory (EMBL), Hamburg Unit, 22607 Hamburg, Germany
| | - Melissa A Gräwert
- European Molecular Biology Laboratory (EMBL), Hamburg Unit, 22607 Hamburg, Germany
| | - Pedro F Aramendia
- Centro de Investigaciones en Bionanociencias 'Elizabeth Jares-Erijman' CIBION, CONICET, Buenos Aires C1425FQD, Argentina
- Departamento de Química Inorgánica, Analítica y Química Física, FCEN, Universidad de Buenos Aires, Buenos Aires C1428EHA, Argentina
| | - Alejandro E Leroux
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA)-CONICET-Partner Institute of the Max Planck Society, Buenos Aires C1425FQD, Argentina
| | - Barry V L Potter
- Medicinal Chemistry and Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK
- Wolfson Laboratory of Medicinal Chemistry, Department of Life Sciences, University of Bath, Claverton Down, Bath BA2 7AY, UK
| | - Carlos J Camacho
- Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Ricardo M Biondi
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA)-CONICET-Partner Institute of the Max Planck Society, Buenos Aires C1425FQD, Argentina
- Department of Internal Medicine I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
- DKTK German Cancer Consortium (DKTK), Frankfurt, Germany
- German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany
| |
Collapse
|
2
|
Garcia-Viloca M, Bayascas JR, Lluch JM, González-Lafont À. Molecular Insights into the Regulation of 3-Phosphoinositide-Dependent Protein Kinase 1: Modeling the Interaction between the Kinase and the Pleckstrin Homology Domains. ACS OMEGA 2022; 7:25186-25199. [PMID: 35910176 PMCID: PMC9330272 DOI: 10.1021/acsomega.2c02020] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
The 3-phosphoinositide-dependent protein kinase 1 (PDK1) K465E mutant kinase can still activate protein kinase B (PKB) at the membrane in a phosphatidylinositol-3,4,5-trisphosphate (PIP3, PtdIns(3,4,5)P3) independent manner. To understand this new PDK1 regulatory mechanism, docking and molecular dynamics calculations were performed for the first time to simulate the wild-type kinase domain-pleckstrin homology (PH) domain complex with PH-in and PH-out conformations. These simulations were then compared to the PH-in model of the KD-PH(mutant K465E) PDK1 complex. Additionally, three KD-PH complexes were simulated, including a substrate analogue bound to a hydrophobic pocket (denominated the PIF-pocket) substrate-docking site. We find that only the PH-out conformation, with the PH domain well-oriented to interact with the cellular membrane, is active for wild-type PDK1. In contrast, the active conformation of the PDK1 K465E mutant is PH-in, being ATP-stable at the active site while the PIF-pocket is more accessible to the peptide substrate. We corroborate that both the docking-site binding and the catalytic activity are in fact enhanced in knock-in mouse samples expressing the PDK1 K465E protein, enabling the phosphorylation of PKB in the absence of PIP3 binding.
Collapse
Affiliation(s)
- Mireia Garcia-Viloca
- Departament
de Química, Universitat Autònoma
de Barcelona, Bellaterra, Barcelona 08193, Spain
| | - Jose Ramón Bayascas
- Institut
de Neurociències, Universitat Autònoma
de Barcelona, Bellaterra, Barcelona 08193, Spain
- Department
of Biochemistry and Molecular Biology, Biochemistry Unit of the School
of Medicine, Universitat Autònoma
de Barcelona, Bellaterra, Barcelona 08193, Spain
| | - José M. Lluch
- Departament
de Química, Universitat Autònoma
de Barcelona, Bellaterra, Barcelona 08193, Spain
- Institut
de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain
| | - Àngels González-Lafont
- Departament
de Química, Universitat Autònoma
de Barcelona, Bellaterra, Barcelona 08193, Spain
- Institut
de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain
| |
Collapse
|
3
|
Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. Int J Mol Sci 2022; 23:ijms23062919. [PMID: 35328342 PMCID: PMC8949999 DOI: 10.3390/ijms23062919] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 03/03/2022] [Accepted: 03/04/2022] [Indexed: 02/05/2023] Open
Abstract
Multiple myeloma (MM) is characterized by remarkable cytogenetic/molecular heterogeneity among patients and intraclonal diversity even in a single patient. We previously demonstrated that PDPK1, the master kinase of series of AGC kinases, is universally active in MM, and plays pivotal roles in cell proliferation and cell survival of myeloma cells regardless of the profiles of cytogenetic and genetic abnormalities. This study investigated the therapeutic efficacy and mechanism of action of dual blockade of two major PDPK1 substrates, RSK2 and AKT, in MM. The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation. Moreover, the dual blockade of RSK2 and AKT exerted robust molecular effects on critical gene sets associated with myeloma pathophysiologies, such as those with MYC, mTOR, STK33, ribosomal biogenesis, or cell-extrinsic stimuli of soluble factors, in HMCLs. These results provide the biological and molecular rationales for the dual-targeting strategy for RSK2 and AKT, which may overcome the therapeutic difficulty due to cytogenetic/molecular heterogeneity in MM.
Collapse
Affiliation(s)
- Reiko Isa
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Mano Horinaka
- Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (M.H.); (S.Y.); (T.S.)
| | - Taku Tsukamoto
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Kentaro Mizuhara
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Yuto Fujibayashi
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Yoko Taminishi-Katsuragawa
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Haruya Okamoto
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Shusuke Yasuda
- Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (M.H.); (S.Y.); (T.S.)
| | - Yuka Kawaji-Kanayama
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Yayoi Matsumura-Kimoto
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Shinsuke Mizutani
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Yuji Shimura
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
| | - Masafumi Taniwaki
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
- Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
| | - Toshiyuki Sakai
- Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (M.H.); (S.Y.); (T.S.)
| | - Junya Kuroda
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; (R.I.); (T.T.); (K.M.); (Y.F.); (Y.T.-K.); (H.O.); (Y.K.-K.); (Y.M.-K.); (S.M.); (Y.S.); (M.T.)
- Correspondence:
| |
Collapse
|
4
|
Schneider B, Baudry A, Pietri M, Alleaume-Butaux A, Bizingre C, Nioche P, Kellermann O, Launay JM. The Cellular Prion Protein-ROCK Connection: Contribution to Neuronal Homeostasis and Neurodegenerative Diseases. Front Cell Neurosci 2021; 15:660683. [PMID: 33912016 PMCID: PMC8072021 DOI: 10.3389/fncel.2021.660683] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 03/15/2021] [Indexed: 01/10/2023] Open
Abstract
Amyloid-based neurodegenerative diseases such as prion, Alzheimer's, and Parkinson's diseases have distinct etiologies and clinical manifestations, but they share common pathological events. These diseases are caused by abnormally folded proteins (pathogenic prions PrPSc in prion diseases, β-amyloids/Aβ and Tau in Alzheimer's disease, α-synuclein in Parkinson's disease) that display β-sheet-enriched structures, propagate and accumulate in the nervous central system, and trigger neuronal death. In prion diseases, PrPSc-induced corruption of the physiological functions exerted by normal cellular prion proteins (PrPC) present at the cell surface of neurons is at the root of neuronal death. For a decade, PrPC emerges as a common cell surface receptor for other amyloids such as Aβ and α-synuclein, which relays, at least in part, their toxicity. In lipid-rafts of the plasma membrane, PrPC exerts a signaling function and controls a set of effectors involved in neuronal homeostasis, among which are the RhoA-associated coiled-coil containing kinases (ROCKs). Here we review (i) how PrPC controls ROCKs, (ii) how PrPC-ROCK coupling contributes to neuronal homeostasis, and (iii) how the deregulation of the PrPC-ROCK connection in amyloid-based neurodegenerative diseases triggers a loss of neuronal polarity, affects neurotransmitter-associated functions, contributes to the endoplasmic reticulum stress cascade, renders diseased neurons highly sensitive to neuroinflammation, and amplifies the production of neurotoxic amyloids.
Collapse
Affiliation(s)
- Benoit Schneider
- Inserm UMR-S1124, Paris, France.,Université de Paris, Faculté des Sciences, Paris, France
| | - Anne Baudry
- Inserm UMR-S1124, Paris, France.,Université de Paris, Faculté des Sciences, Paris, France
| | - Mathéa Pietri
- Inserm UMR-S1124, Paris, France.,Université de Paris, Faculté des Sciences, Paris, France
| | - Aurélie Alleaume-Butaux
- Inserm UMR-S1124, Paris, France.,Université de Paris, Faculté des Sciences, Paris, France.,Université de Paris - BioMedTech Facilities- INSERM US36
- CNRS UMS2009 - Structural and Molecular Analysis Platform, Paris, France
| | - Chloé Bizingre
- Inserm UMR-S1124, Paris, France.,Université de Paris, Faculté des Sciences, Paris, France
| | - Pierre Nioche
- Inserm UMR-S1124, Paris, France.,Université de Paris, Faculté des Sciences, Paris, France.,Université de Paris - BioMedTech Facilities- INSERM US36
- CNRS UMS2009 - Structural and Molecular Analysis Platform, Paris, France
| | - Odile Kellermann
- Inserm UMR-S1124, Paris, France.,Université de Paris, Faculté des Sciences, Paris, France
| | - Jean-Marie Launay
- Inserm UMR 942, Hôpital Lariboisière, Paris, France.,Pharma Research Department, Hoffmann-La-Roche Ltd., Basel, Switzerland
| |
Collapse
|
5
|
He S, Yin X, Wu F, Zeng S, Gao F, Xin M, Wang J, Chen J, Zhang L, Zhang J. Hyperoside protects cardiomyocytes against hypoxia‑induced injury via upregulation of microRNA‑138. Mol Med Rep 2021; 23:286. [PMID: 33649812 PMCID: PMC7905326 DOI: 10.3892/mmr.2021.11925] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Accepted: 01/11/2021] [Indexed: 12/25/2022] Open
Abstract
Following hypoxia, cardiomyocytes are susceptible to damage, against which microRNA (miR)‑138 may act protectively. Hyperoside (Hyp) is a Chinese herbal medicine with multiple biological functions that serve an important role in cardiovascular disease. The aim of the present study was to investigate the role of Hyp in hypoxic cardiomyocytes and its effect on miR‑138. A hypoxia model was established in both H9C2 cells and C57BL/6 mice, which were stimulated by Hyp. The expression levels of miR‑138 were increased in the hypoxic myocardium in the presence of Hyp at concentrations of >50 µmol/l in vivo and >50 mg/kg in vitro. Using Cell Counting Kit‑8 and 5‑ethynyl‑2'‑deoxyuridine assays, it was observed that Hyp improved hypoxia‑induced impairment of cell proliferation. Cell apoptosis was evaluated by flow cytometry and a TUNEL assay. The number of apoptotic cells in the Hyp group was lower than that in the control group. As markers of myocardial injury, the levels of lactate dehydrogenase, creatine kinase‑myocardial band isoenzyme and malondialdehyde were decreased in the Hyp group compared with the control group, whereas the levels of superoxide dismutase were increased. A marked decrease in the levels of cleaved caspase‑3 and cleaved poly(ADP) ribose polymerase and a marked increase in expression levels of Bcl‑2 were observed in the presence of Hyp. However, miR‑138 inhibition by antagomir attenuated the protective effects of Hyp. Furthermore, Hyp treatment was associated with marked downregulation of mixed lineage kinase 3 and lipocalin‑2, but not pyruvate dehydrogenase kinase 1, in hypoxic H9C2 cells. These findings demonstrated that Hyp may be beneficial for myocardial cell survival and may alleviate hypoxic injury via upregulation of miR‑138, thereby representing a promising potential strategy for clinical cardioprotection.
Collapse
Affiliation(s)
- Siyi He
- Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
| | - Xiaoqiang Yin
- Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
- Department of Graduate Student, North Sichuan Medical College, Nanchong, Sichuan 637199, P.R. China
| | - Fan Wu
- Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
| | - Shaojie Zeng
- Medical Team, Unit 95437, People's Liberation Army, Nanchong, Sichuan 637100, P.R. China
| | - Feng Gao
- Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
| | - Mei Xin
- Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
| | - Jian Wang
- Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
| | - Jie Chen
- Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
| | - Le Zhang
- National Drug Clinical Trial Institution, Second Affiliated Hospital, Army Medical University, Chongqing 400037, P.R. China
| | - Jinbao Zhang
- Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
| |
Collapse
|
6
|
Liu J, Xie X, Yan D, Wang Y, Yuan H, Cai Y, Luo J, Xu A, Huang Y, Cheung CW, Irwin MG, Xia Z. Up-regulation of FoxO1 contributes to adverse vascular remodelling in type 1 diabetic rats. J Cell Mol Med 2020; 24:13727-13738. [PMID: 33108705 PMCID: PMC7754018 DOI: 10.1111/jcmm.15935] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 09/08/2020] [Accepted: 09/10/2020] [Indexed: 02/06/2023] Open
Abstract
Vascular complications from diabetes often result in poor outcomes for patients, even after optimized interventions. Forkhead box protein O1 (FoxO1) is a key regulator of cellular metabolism and plays an important role in vessel formation and maturation. Alterations of FoxO1 occur in the cardiovascular system in diabetes, yet the role of FoxO1 in diabetic vascular complications is poorly understood. In Streptozotocin (STZ)‐induced type 1 diabetic rats, FoxO1 expression was up‐regulated in carotid arteries at 8 weeks of diabetes that was accompanied with adverse vascular remodelling characterized as increased wall thickness, carotid medial cross‐sectional area, media‐to‐lumen ratio and decreased carotid artery lumen area. This adverse vascular remodelling induced by hyperglycaemia in diabetic rats required FoxO1 activation as pharmacological inhibition of FoxO1 with 50mg/kg AS1842856 (AS) reversed vascular remodelling in type 1 diabetic rats. The adverse vascular remodelling in type 1 diabetes mellitus (T1DM) occurred concomitantly with increases in pro‐inflammatory factors, adhesion factors, apoptosis, NOD‐like receptor family protein‐3 inflammasome activation and the phenotypic switch of arterial smooth muscle cells, which were all reversed by AS. In addition, FoxO1 inhibition counteracted the down‐regulation of its upstream mediator PDK1 in T1DM. PDK1 activator reduced FoxO1 nuclear translocation, which serves as the basis for subsequent transcriptional regulation during hyperglycaemia. Taken together, our data suggest that FoxO1 is a critical trigger for type 1 diabetes‐induced vascular remodelling in rats, and inhibition of FoxO1 thus offers a potential therapeutic option for diabetes‐associated cardiovascular diseases.
Collapse
Affiliation(s)
- Jingjin Liu
- Department of Anesthesiology, University of Hong Kong, Hong Kong, China
| | - Xiang Xie
- Department of Anesthesiology, University of Hong Kong, Hong Kong, China.,Department of Anesthesiology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China
| | - Dan Yan
- Department of Anesthesiology, University of Hong Kong, Hong Kong, China
| | - Yongshun Wang
- Department of Biomedical Science, University of Hong Kong, Hong Kong, China
| | - Hongbin Yuan
- Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, Shanghai, China
| | - Yin Cai
- Department of Anesthesiology, University of Hong Kong, Hong Kong, China
| | - Jierong Luo
- Department of Anesthesiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Aimin Xu
- State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong, China
| | - Yu Huang
- Heart and Vascular Institute and School of Biomedical Sciences, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Chi Wai Cheung
- Department of Anesthesiology, University of Hong Kong, Hong Kong, China
| | - Michael G Irwin
- Department of Anesthesiology, University of Hong Kong, Hong Kong, China
| | - Zhengyuan Xia
- Department of Anesthesiology, University of Hong Kong, Hong Kong, China.,State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong, China
| |
Collapse
|
7
|
Heras-Martínez GDL, Calleja V, Bailly R, Dessolin J, Larijani B, Requejo-Isidro J. A Complex Interplay of Anionic Phospholipid Binding Regulates 3'-Phosphoinositide-Dependent-Kinase-1 Homodimer Activation. Sci Rep 2019; 9:14527. [PMID: 31601855 PMCID: PMC6787260 DOI: 10.1038/s41598-019-50742-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Accepted: 09/16/2019] [Indexed: 12/28/2022] Open
Abstract
3'-Phosphoinositide-dependent-Kinase-1 (PDK1) is a master regulator whereby its PI3-kinase-dependent dysregulation in human pathologies is well documented. Understanding the direct role for PtdIns(3,4,5)P3 and other anionic phospholipids in the regulation of PDK1 conformational dynamics and its downstream activation remains incomplete. Using advanced quantitative-time-resolved imaging (Fluorescence Lifetime Imaging and Fluorescence Correlation Spectroscopy) and molecular modelling, we show an interplay of antagonistic binding effects of PtdIns(3,4,5)P3 and other anionic phospholipids, regulating activated PDK1 homodimers. We demonstrate that phosphatidylserine maintains PDK1 in an inactive conformation. The dysregulation of the PI3K pathway affects the spatio-temporal and conformational dynamics of PDK1 and the activation of its downstream substrates. We have established a new anionic-phospholipid-dependent model for PDK1 regulation, depicting the conformational dynamics of multiple homodimer states. We show that the dysregulation of the PI3K pathway perturbs equilibrium between the PDK1 homodimer conformations. Our findings provide a role for the PtdSer binding site and its previously unrewarding role in PDK1 downregulation, suggesting a possible therapeutic strategy where the constitutively active dimer conformer of PDK1 may be rendered inactive by small molecules that drive it to its PtdSer-bound conformer.
Collapse
Affiliation(s)
- Gloria de Las Heras-Martínez
- Instituto Biofisika (CSIC, UPV/EHU), 48490, Leioa, Spain
- Cell Biophysics Laboratory, Ikerbasque Basque Foundation for Science, Instituto Biofisika (CSIC, UPV/EHU) & Research Centre for Experimental Marine Biology and Biotechnology (PiE), University of the Basque Country (UPV/EHU), Leioa, 48940, Spain
| | - Véronique Calleja
- Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, UK
| | - Remy Bailly
- Institute of Chemistry & Biology of Membranes & Nanoobjects (UMR 5248 CBMN) CNRS - Université de Bordeaux - Bordeaux INP All. Geoffroy Saint-Hilaire, 33600, Pessac, France
| | - Jean Dessolin
- Institute of Chemistry & Biology of Membranes & Nanoobjects (UMR 5248 CBMN) CNRS - Université de Bordeaux - Bordeaux INP All. Geoffroy Saint-Hilaire, 33600, Pessac, France
| | - Banafshé Larijani
- Cell Biophysics Laboratory, Ikerbasque Basque Foundation for Science, Instituto Biofisika (CSIC, UPV/EHU) & Research Centre for Experimental Marine Biology and Biotechnology (PiE), University of the Basque Country (UPV/EHU), Leioa, 48940, Spain.
- Centre for Therapeutic Innovation (CTI-Bath); Cell Biophysics Laboratory Department of Pharmacy & Pharmacology University, Bath, Claverton Down, Bath, BA2 7AY, United Kingdom.
| | - Jose Requejo-Isidro
- Instituto Biofisika (CSIC, UPV/EHU), 48490, Leioa, Spain.
- Centro Nacional de Biotecnología (CSIC), Darwin, 3, E28049, Madrid, Spain.
- Unidad de Nanobiotecnología, CNB-CSIC-IMDEA Nanociencia Associated Unit, 28049, Madrid, Spain.
| |
Collapse
|
8
|
Ezpeleta J, Baudouin V, Arellano-Anaya ZE, Boudet-Devaud F, Pietri M, Baudry A, Haeberlé AM, Bailly Y, Kellermann O, Launay JM, Schneider B. Production of seedable Amyloid-β peptides in model of prion diseases upon PrP Sc-induced PDK1 overactivation. Nat Commun 2019; 10:3442. [PMID: 31371707 PMCID: PMC6672003 DOI: 10.1038/s41467-019-11333-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Accepted: 07/09/2019] [Indexed: 02/07/2023] Open
Abstract
The presence of amyloid beta (Aβ) plaques in the brain of some individuals with Creutzfeldt-Jakob or Gertsmann-Straussler-Scheinker diseases suggests that pathogenic prions (PrPSc) would have stimulated the production and deposition of Aβ peptides. We here show in prion-infected neurons and mice that deregulation of the PDK1-TACE α-secretase pathway reduces the Amyloid Precursor Protein (APP) α-cleavage in favor of APP β-processing, leading to Aβ40/42 accumulation. Aβ predominates as monomers, but is also found as trimers and tetramers. Prion-induced Aβ peptides do not affect prion replication and infectivity, but display seedable properties as they can deposit in the mouse brain only when seeds of Aβ trimers are co-transmitted with PrPSc. Importantly, brain Aβ deposition accelerates death of prion-infected mice. Our data stress that PrPSc, through deregulation of the PDK1-TACE-APP pathway, provokes the accumulation of Aβ, a prerequisite for the onset of an Aβ seeds-induced Aβ pathology within a prion-infectious context. Aβ plaques have been detected in brains of patients with prion diseases. Here, using mice, the authors show that prion infection enhances Aβ production via a PDK1-TACE mechanism and that brain deposition of Aβ induced by Aβ seeds co-transmitted with PrPSc contributes to mortality in prion disease.
Collapse
Affiliation(s)
- Juliette Ezpeleta
- Université Paris Descartes, Sorbonne Paris Cité, UFR des Sciences Fondamentales et Biomédicales, UMR 1124, 75006, Paris, France.,INSERM, UMR 1124, 75006, Paris, France
| | - Vincent Baudouin
- Université Paris Descartes, Sorbonne Paris Cité, UFR des Sciences Fondamentales et Biomédicales, UMR 1124, 75006, Paris, France.,INSERM, UMR 1124, 75006, Paris, France
| | - Zaira E Arellano-Anaya
- Université Paris Descartes, Sorbonne Paris Cité, UFR des Sciences Fondamentales et Biomédicales, UMR 1124, 75006, Paris, France.,INSERM, UMR 1124, 75006, Paris, France
| | - François Boudet-Devaud
- Université Paris Descartes, Sorbonne Paris Cité, UFR des Sciences Fondamentales et Biomédicales, UMR 1124, 75006, Paris, France.,INSERM, UMR 1124, 75006, Paris, France
| | - Mathéa Pietri
- Université Paris Descartes, Sorbonne Paris Cité, UFR des Sciences Fondamentales et Biomédicales, UMR 1124, 75006, Paris, France.,INSERM, UMR 1124, 75006, Paris, France
| | - Anne Baudry
- Université Paris Descartes, Sorbonne Paris Cité, UFR des Sciences Fondamentales et Biomédicales, UMR 1124, 75006, Paris, France.,INSERM, UMR 1124, 75006, Paris, France
| | - Anne-Marie Haeberlé
- Trafic Membranaire dans les Cellules du Système Nerveux, Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR 3212, 67000, Strasbourg, France
| | - Yannick Bailly
- Trafic Membranaire dans les Cellules du Système Nerveux, Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR 3212, 67000, Strasbourg, France
| | - Odile Kellermann
- Université Paris Descartes, Sorbonne Paris Cité, UFR des Sciences Fondamentales et Biomédicales, UMR 1124, 75006, Paris, France.,INSERM, UMR 1124, 75006, Paris, France
| | - Jean-Marie Launay
- Assistance Publique des Hôpitaux de Paris, INSERM UMR 942, Hôpital Lariboisière, 75010, Paris, France. .,Pharma Research Department, Hoffmann La Roche Ltd, 4070, Basel, Switzerland.
| | - Benoit Schneider
- Université Paris Descartes, Sorbonne Paris Cité, UFR des Sciences Fondamentales et Biomédicales, UMR 1124, 75006, Paris, France. .,INSERM, UMR 1124, 75006, Paris, France.
| |
Collapse
|
9
|
Roth SW, Bitterman MD, Birnbaum MJ, Bland ML. Innate Immune Signaling in Drosophila Blocks Insulin Signaling by Uncoupling PI(3,4,5)P 3 Production and Akt Activation. Cell Rep 2019. [PMID: 29514084 PMCID: PMC5866056 DOI: 10.1016/j.celrep.2018.02.033] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
In obese adipose tissue, Toll-like receptor signaling in macrophages leads to insulin resistance in adipocytes. Similarly, Toll signaling in the Drosophila larval fat body blocks insulin-dependent growth and nutrient storage. We find that Toll acts cell autonomously to block growth but not PI(3,4,5)P3 production in fat body cells expressing constitutively active PI3K. Fat body Toll signaling blocks whole-animal growth in rictor mutants lacking TORC2 activity, but not in larvae lacking Pdk1. Phosphorylation of Akt on the Pdk1 site, Thr342, is significantly reduced by Toll signaling, and expression of mutant AktT342D rescues cell and animal growth, nutrient storage, and viability in animals with active Toll signaling. Altogether, these data show that innate immune signaling blocks insulin signaling at a more distal level than previously appreciated, and they suggest that manipulations affecting the Pdk1 arm of the pathway may have profound effects on insulin sensitivity in inflamed tissues.
Collapse
Affiliation(s)
- Stephen W Roth
- Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA
| | - Moshe D Bitterman
- Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Morris J Birnbaum
- Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Michelle L Bland
- Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
| |
Collapse
|
10
|
Abstract
INTRODUCTION 3-Phosphoinositide-dependent kinase 1 (PDK1), the 'master kinase of the AGC protein kinase family', plays a key role in cancer development and progression. Although it has been rather overlooked, in the last decades a growing number of molecules have been developed to effectively modulate the PDK1 enzyme. AREAS COVERED This review collects different PDK1 inhibitors patented from October 2014 to December 2018. The molecules have been classified on the basis of the chemical structure/type of inhibition, and for each general structure, examples have been discussed in extenso. EXPERT OPINION The role of PDK1 in cancer development and progression as well as in metastasis formation and in chemoresistance has been confirmed by many studies. Therefore, the pharmaceutical discovery in both public and private institutions is still ongoing despite the plentiful molecules already published. The majority of the new molecules synthetized interact with binding sites different from the ATP binding site (i.e. PIF pocket or DFG-out conformation). However, many researchers are still looking for innovative PDK1 modulation strategy such as combination of well-known inhibitory agents or multitarget ligands, aiming to block, together with PDK1, other different critical players in the wide panorama of proteins involved in tumor pathways.
Collapse
Affiliation(s)
- Simona Sestito
- a Department of Pharmacy , University of Pisa , Pisa , Italy
| | | |
Collapse
|
11
|
Picco ME, Castro MV, Quezada MJ, Barbero G, Villanueva MB, Fernández NB, Kim H, Lopez-Bergami P. STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1. Cell Biosci 2019; 9:3. [PMID: 30622697 PMCID: PMC6317239 DOI: 10.1186/s13578-018-0265-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Accepted: 12/21/2018] [Indexed: 01/26/2023] Open
Abstract
Background The PI3K/Akt and the STAT3 pathways are functionally associated in many tumor types. Both in vitro and in vivo studies have revealed that either biochemical or genetic manipulation of the STAT3 pathway activity induce changes in the same direction in Akt activity. However, the implicated mechanism has been poorly characterized. Our goal was to characterize the precise mechanism linking STAT3 with the activity of Akt and other AGC kinases in cancer using melanoma cells as a model. Results We show that active STAT3 is constitutively bound to the PDK1 promoter and positively regulate PDK1 transcription through two STAT3 responsive elements. Transduction of WM9 and UACC903 melanoma cells with STAT3-small hairpin RNA decreased both PDK1 mRNA and protein levels. STAT3 knockdown also induced a decrease of the phosphorylation of AGC kinases Akt, PKC, and SGK. The inhibitory effect of STAT3 silencing on Akt phosphorylation was restored by HA-PDK1. Along this line, HA-PDK1 expression significantly blocked the cell death induced by dacarbazine plus STAT3 knockdown. This effect might be mediated by Bcl2 proteins since HA-PDK1 rescued Bcl2, Bcl-XL, and Mcl1 levels that were down-regulated upon STAT3 silencing. Conclusions We show that PDK1 is a transcriptional target of STAT3, linking STAT3 pathway with AGC kinases activity in melanoma. These data provide further rationale for the ongoing effort to therapeutically target STAT3 and PDK1 in melanoma and, possibly, other malignancies. Electronic supplementary material The online version of this article (10.1186/s13578-018-0265-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- María Elisa Picco
- 1Instituto de Medicina y Biología Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - María Victoria Castro
- 2Centro de Estudios Biomédicos, Biotecnológicos, Ambientales y Diagnóstico (CEBBAD), Universidad Maimónides, CONICET, Hidalgo 775, 6th Floor, Lab 602, Buenos Aires, Argentina
| | - María Josefina Quezada
- 2Centro de Estudios Biomédicos, Biotecnológicos, Ambientales y Diagnóstico (CEBBAD), Universidad Maimónides, CONICET, Hidalgo 775, 6th Floor, Lab 602, Buenos Aires, Argentina
| | - Gastón Barbero
- 2Centro de Estudios Biomédicos, Biotecnológicos, Ambientales y Diagnóstico (CEBBAD), Universidad Maimónides, CONICET, Hidalgo 775, 6th Floor, Lab 602, Buenos Aires, Argentina
| | - María Belén Villanueva
- 2Centro de Estudios Biomédicos, Biotecnológicos, Ambientales y Diagnóstico (CEBBAD), Universidad Maimónides, CONICET, Hidalgo 775, 6th Floor, Lab 602, Buenos Aires, Argentina
| | - Natalia Brenda Fernández
- 1Instituto de Medicina y Biología Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Hyungsoo Kim
- 3Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA USA
| | - Pablo Lopez-Bergami
- 2Centro de Estudios Biomédicos, Biotecnológicos, Ambientales y Diagnóstico (CEBBAD), Universidad Maimónides, CONICET, Hidalgo 775, 6th Floor, Lab 602, Buenos Aires, Argentina
| |
Collapse
|
12
|
microRNA-378 promotes autophagy and inhibits apoptosis in skeletal muscle. Proc Natl Acad Sci U S A 2018; 115:E10849-E10858. [PMID: 30373812 DOI: 10.1073/pnas.1803377115] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The metabolic regulation of cell death is sophisticated. A growing body of evidence suggests the existence of multiple metabolic checkpoints that dictate cell fate in response to metabolic fluctuations. However, whether microRNAs (miRNAs) are able to respond to metabolic stress, reset the threshold of cell death, and attempt to reestablish homeostasis is largely unknown. Here, we show that miR-378/378* KO mice cannot maintain normal muscle weight and have poor running performance, which is accompanied by impaired autophagy, accumulation of abnormal mitochondria, and excessive apoptosis in skeletal muscle, whereas miR-378 overexpression is able to enhance autophagy and repress apoptosis in skeletal muscle of mice. Our in vitro data show that metabolic stress-responsive miR-378 promotes autophagy and inhibits apoptosis in a cell-autonomous manner. Mechanistically, miR-378 promotes autophagy initiation through the mammalian target of rapamycin (mTOR)/unc-51-like autophagy activating kinase 1 (ULK1) pathway and sustains autophagy via Forkhead box class O (FoxO)-mediated transcriptional reinforcement by targeting phosphoinositide-dependent protein kinase 1 (PDK1). Meanwhile, miR-378 suppresses intrinsic apoptosis initiation directly through targeting an initiator caspase-Caspase 9. Thus, we propose that miR-378 is a critical component of metabolic checkpoints, which integrates metabolic information into an adaptive response to reduce the propensity of myocytes to undergo apoptosis by enhancing the autophagic process and blocking apoptotic initiation. Lastly, our data suggest that inflammation-induced down-regulation of miR-378 might contribute to the pathogenesis of muscle dystrophy.
Collapse
|
13
|
Role for loss of nuclear PTEN in a harbinger of brain metastases. J Clin Neurosci 2017; 44:148-154. [DOI: 10.1016/j.jocn.2017.06.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2017] [Accepted: 06/08/2017] [Indexed: 12/21/2022]
|
14
|
Leroux AE, Schulze JO, Biondi RM. AGC kinases, mechanisms of regulation and innovative drug development. Semin Cancer Biol 2017; 48:1-17. [PMID: 28591657 DOI: 10.1016/j.semcancer.2017.05.011] [Citation(s) in RCA: 92] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Revised: 05/16/2017] [Accepted: 05/31/2017] [Indexed: 12/22/2022]
Abstract
The group of AGC kinases consists of 63 evolutionarily related serine/threonine protein kinases comprising PDK1, PKB/Akt, SGK, PKC, PRK/PKN, MSK, RSK, S6K, PKA, PKG, DMPK, MRCK, ROCK, NDR, LATS, CRIK, MAST, GRK, Sgk494, and YANK, while two other families, Aurora and PLK, are the most closely related to the group. Eight of these families are physiologically activated downstream of growth factor signalling, while other AGC kinases are downstream effectors of a wide range of signals. The different AGC kinase families share aspects of their mechanisms of inhibition and activation. In the present review, we update the knowledge of the mechanisms of regulation of different AGC kinases. The conformation of the catalytic domain of many AGC kinases is regulated allosterically through the modulation of the conformation of a regulatory site on the small lobe of the kinase domain, the PIF-pocket. The PIF-pocket acts like an ON-OFF switch in AGC kinases with different modes of regulation, i.e. PDK1, PKB/Akt, LATS and Aurora kinases. In this review, we make emphasis on how the knowledge of the molecular mechanisms of regulation can guide the discovery and development of small allosteric modulators. Molecular probes stabilizing the PIF-pocket in the active conformation are activators, while compounds stabilizing the disrupted site are allosteric inhibitors. One challenge for the rational development of allosteric modulators is the lack of complete structural information of the inhibited forms of full-length AGC kinases. On the other hand, we suggest that the available information derived from molecular biology and biochemical studies can already guide screening strategies for the identification of innovative mode of action molecular probes and the development of selective allosteric drugs for the treatment of human diseases.
Collapse
Affiliation(s)
- Alejandro E Leroux
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires C1425FQD, Argentina.
| | - Jörg O Schulze
- Research Group PhosphoSites, Medizinische Klinik 1, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
| | - Ricardo M Biondi
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires C1425FQD, Argentina; Research Group PhosphoSites, Medizinische Klinik 1, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany.
| |
Collapse
|
15
|
Yang Y, Kong W, Xia Z, Xiao L, Wang S. Regulation mechanism of PDK1 on macrophage metabolism and function. Cell Biochem Funct 2016; 34:546-553. [DOI: 10.1002/cbf.3235] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Revised: 09/11/2016] [Accepted: 10/11/2016] [Indexed: 01/21/2023]
Affiliation(s)
- Yueqin Yang
- Exercise Intervention and Health Promotion Hubei Province Synergy Innovation Center; Wuhan Sports University; Wuhan Hubei China
| | - Weiwei Kong
- Graduate School; Wuhan Sports University; Wuhan Hubei China
| | - Zhi Xia
- Exercise Physiology and Biochemical Laboratory, College of Physical Education; Jinggangshan University; Ji'an Jiangxi China
| | - Lin Xiao
- School of Physical Education and Health Science; Zhaoqing University; Zhaoqing Guangdong China
| | - Song Wang
- Exercise Intervention and Health Promotion Hubei Province Synergy Innovation Center; Wuhan Sports University; Wuhan Hubei China
| |
Collapse
|
16
|
Wang J, Liu F, Ao P, Li X, Zheng H, Wu D, Zhang N, She J, Yuan J, Wu X. Correlation of PDK1 expression with clinicopathologic features and prognosis of hepatocellular carcinoma. Onco Targets Ther 2016; 9:5597-602. [PMID: 27672330 PMCID: PMC5024765 DOI: 10.2147/ott.s110646] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Objective To explore the clinical significance of 3-phosphoinositide-dependent protein kinase-1 (PDK1) expression in hepatocellular carcinoma (HCC) and its association with clinicopathologic features and prognosis in HCC patients. Materials and methods A total of 128 HCC patients who received radical resection were enrolled from Wenling Maternal and Child Health Care Hospital between May 2005 and December 2008, and tumor and adjacent tissue samples were collected. Expression of PDK1 was detected by immunohistochemistry method. Correlation of PDK1 expression with clinicopathological features and prognosis was determined by Spearman’s correlation analysis. Impact of expression of PDK1 on overall survival and recurrence was determined by Kaplan–Meier analysis. Results Immunohistochemistry results showed that PDK1 expression in HCC tissues was significantly higher than that in the corresponding adjacent cancer tissues. Univariate analysis showed that PDK1 messenger RNA expression can predict time to recurrence with diagnostic significance (P=0.001). Univariate analysis showed that alpha-fetoprotein level, tumor number, tumor encapsulation, microvascular invasion, and tumor–node–metastasis stage were also unfavorable prognostic variables for recurrence (P<0.05). Kaplan–Meier analysis showed that overexpression of PDK1 correlates with significantly shorter postoperative overall survival and higher recurrence rates (hazard ratio =2.68; 95% confidence interval: 2.46–4.42, P=0.001) in HCC patients after curative resection. Conclusion Our study indicated that PDK1 may serve as a candidate pro-oncogene and a potential prognostic biomarker for HCC.
Collapse
Affiliation(s)
- Junrong Wang
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Fenqin Liu
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Peiran Ao
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Xianneng Li
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Haixiao Zheng
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Di Wu
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Nina Zhang
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Junping She
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Junhui Yuan
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| | - Xiuying Wu
- Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China
| |
Collapse
|
17
|
Watanabe S, Matsumoto T, Ando M, Adachi T, Kobayashi S, Iguchi M, Takeuchi M, Taguchi K, Kobayashi T. Multiple activation mechanisms of serotonin-mediated contraction in the carotid arteries obtained from spontaneously hypertensive rats. Pflugers Arch 2016; 468:1271-1282. [PMID: 27170312 DOI: 10.1007/s00424-016-1834-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Revised: 04/29/2016] [Accepted: 05/02/2016] [Indexed: 12/21/2022]
Abstract
Serotonin (5-hydroxytryptamine, 5-HT) is an important endogenous substance that regulates the vascular tone, and the abnormal signaling of 5-HT has been observed in the arteries under several pathophysiological conditions such as diabetes and hypertension. However, signaling pathways of 5-HT-mediated vasocontraction in hypertension remain unclear. Therefore, we tested the hypothesis that 5-HT-mediated contraction and contributions of various kinases such as mitogen-activated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K), Rho kinase (ROCK), and 3-phosphoinositide-dependent kinase 1 (PDK1) to the contraction would be altered in the carotid arteries obtained from spontaneously hypertensive rats (SHR) compared to control Wistar Kyoto (WKY) rats. In the carotid arteries from SHR (vs. those from WKY), (1) the 5-HT-mediated contraction was increased, whereas the norepinephrine-mediated contraction was not; (2) 5-HT-mediated contractions were partly inhibited by each kinase (extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAPK, c-Jun N-terminal kinase (JNK), PI3K, ROCK, and PDK1) inhibitor; and (3) 5-HT-stimulated phosphorylation of ERK1/2, p38 MAPK, JNK, myosin phosphatase target subunit 1 (MYPT1), and PDK1 was increased. The expression of ROCK2 but not ROCK1 was increased in the carotid arteries from SHR compared to WKY. The expression of 5-HT2A receptor, a major receptor of 5-HT-mediated contraction in rat carotid artery, was similar in carotid arteries between the two groups. These results suggest that 5-HT-mediated contraction was utilized multiple signaling pathways such as ERK1/2, p38 MAPK, JNK, PI3K, ROCK, and PDK1. Although 5-HT-mediated contraction was increased in the carotid arteries obtained from SHR, further studies are necessary to clarify how each kinase may integrate in the vascular smooth muscles under hypertension.
Collapse
Affiliation(s)
- Shun Watanabe
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Takayuki Matsumoto
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Makoto Ando
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Tsuyuki Adachi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Shota Kobayashi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Maika Iguchi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Miki Takeuchi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Kumiko Taguchi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Tsuneo Kobayashi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan.
| |
Collapse
|
18
|
Pastor-Flores D, Schulze JO, Bahí A, Süß E, Casamayor A, Biondi RM. Lipid regulators of Pkh2 in Candida albicans, the protein kinase ortholog of mammalian PDK1. Biochim Biophys Acta Mol Cell Biol Lipids 2015; 1861:249-59. [PMID: 26743850 DOI: 10.1016/j.bbalip.2015.12.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2015] [Revised: 12/21/2015] [Accepted: 12/24/2015] [Indexed: 11/18/2022]
Abstract
Pkh is the yeast ortholog of the mammalian 3-phosphoinositide-dependent protein kinase 1 (PDK1). Pkh phosphorylates the activation loop of Ypks, Tpks, Sch9 and also phosphorylates the eisosome components Lsp1 and Pil1, which play fundamental roles upstream of diverse signaling pathways, including the cell wall integrity and sphingosine/long-chain base (LCB) signaling pathways. In S. cerevisiae, two isoforms, ScPkh1 and ScPkh2, are required for cell viability, while only one ortholog exists in C. albicans, CaPkh2. In spite of the extensive information gathered on the role of Pkh in the LCB signaling, the yeast Pkh kinases are not known to bind lipids and previous studies did not identify PH domains in Pkh sequences. We now describe that the C-terminal region of CaPkh2 is required for its intrinsic kinase activity. In addition, we found that the C-terminal region of CaPkh2 enables its interaction with structural and signaling lipids. Our results further show that phosphatidylserine, phosphatidic acid, phosphatidylinositol (3,4 and 4,5)-biphosphates, and phosphatidylinositol (3,4,5)-trisphosphate inhibit Pkh activity, whereas sulfatide binds with high affinity but does not affect the intrinsic activity of CaPkh2. Interestingly, we identified that its human ortholog PDK1 also binds to sulfatide. We propose a mechanism by which lipids and dihydrosphingosine regulate CaPkh2 kinase activity by modulating the interaction of the C-terminal region with the kinase domain, while sulfatide-like lipids support localization CaPkh2 mediated by a C-terminal PH domain, without affecting kinase intrinsic activity.
Collapse
Affiliation(s)
- Daniel Pastor-Flores
- Research Group PhosphoSites, Medizinische Klinik 1, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Jörg O Schulze
- Research Group PhosphoSites, Medizinische Klinik 1, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Anna Bahí
- Departament de Bioquímica i Biologia Molecular, Facultat de Veterinària, Universitat Autònoma de Barcelona, Cerdanyola, 08193, Barcelona, Spain; Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, Cerdanyola, 08193, Barcelona, Spain
| | - Evelyn Süß
- Research Group PhosphoSites, Medizinische Klinik 1, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Antonio Casamayor
- Departament de Bioquímica i Biologia Molecular, Facultat de Veterinària, Universitat Autònoma de Barcelona, Cerdanyola, 08193, Barcelona, Spain; Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, Cerdanyola, 08193, Barcelona, Spain.
| | - Ricardo M Biondi
- Research Group PhosphoSites, Medizinische Klinik 1, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
| |
Collapse
|
19
|
Fan Y, Wang Y, Wang K. Prostaglandin E2 stimulates normal bronchial epithelial cell growth through induction of c-Jun and PDK1, a kinase implicated in oncogenesis. Respir Res 2015; 16:149. [PMID: 26684827 PMCID: PMC4699375 DOI: 10.1186/s12931-015-0309-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Accepted: 12/04/2015] [Indexed: 02/05/2023] Open
Abstract
Background Cyclooxygenase-2-derived prostaglandin E2 (PGE2), a bioactive eicosanoid, has been implicated in many biological processes including reproduction, inflammation and tumor growth. We previously showed that PGE2 stimulated lung cancer cell growth and progression through PGE2 receptor EP2/EP4-mediated kinase signaling pathways. However, the role of PGE2 in controlling lung airway epithelial cell phenotype remains unknown. We evaluated the effects of c-Jun and 3-phosphoinositede dependent protein kinase-1 (PDK1) in mediating epithelial cell hyperplasia induced by PGE2. Method The bronchial epithelial cell lines BEAS-2B and HBEc14-KT were cultured and then treated with PGE2. PDK1 small interfering RNA (siRNA) and a PDK1 inhibitor, an antagonist of the PGE2 receptor subtype EP4 and EP4 siRNA, c-Jun siRNA, and overexpressions of c-Jun and PDK1 have been used to evaluate the effects on cell proliferation. Results We demonstrated that PGE2 increased normal bronchial epithelial cell proliferation through induction of PDK1, an ankyrin repeat-containing Ser/Thr kinase implicated in the induction of apoptosis and the suppression of tumor growth. PDK1 siRNA and a PDK1 inhibitor blocked the effects of PGE2 on normal cell growth. The PGE2-induced PDK1 expression was blocked by an antagonist of the PGE2 receptor subtype EP4 and by EP4 siRNA. In addition, we showed that induction of PDK1 by PGE2 was associated with induction of the transcription factor, c-Jun protein. Silencing of c-Jun using siRNA and point mutations of c-Jun sites in the PDK1 gene promoter resulted in blockade of PDK1 expression and promoter activity induced by PGE2. In contrast, overexpression of c-Jun induced PDK1 gene promoter activity and expression followed increased cell proliferation. Conclusion PGE2 increases normal bronchial epithelial cell proliferation through increased PDK1 gene expression that is dependent on EP4 and induction of c-Jun. Therewith, our data suggest a new role of c-Jun and PDK1 in mediating epithelial cell hyperplasia induced by PGE2.
Collapse
Affiliation(s)
- Yu Fan
- Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China. .,Department of Radiotherapy, Sichuan Cancer Hospital, Chengdu, Sichuan Province, 610041, China.
| | - Ye Wang
- Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China.
| | - Ke Wang
- Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China.
| |
Collapse
|
20
|
Watanabe S, Matsumoto T, Oda M, Yamada K, Takagi J, Taguchi K, Kobayashi T. Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery. Pflugers Arch 2015; 468:667-77. [PMID: 26577585 DOI: 10.1007/s00424-015-1759-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Revised: 11/09/2015] [Accepted: 11/11/2015] [Indexed: 10/24/2022]
Abstract
Hyperinsulinemia associated with type 2 diabetes may contribute to the development of vascular diseases. Although we recently reported that enhanced contractile responses to serotonin (5-hydroxytryptamine, 5-HT) are observed in the arteries of type 2 diabetes models, the causative factors and detailed signaling pathways involved remain unclear. The purpose of this study was to investigate whether high insulin would be an amplifier of 5-HT-induced contraction in rat carotid arteries and whether the contraction involves phosphoinositide 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase 1 (PDK1) signaling, an insulin-mediated signaling pathway. In rat carotid arteries organ-cultured with insulin (for 24 h), (1) the contractile responses to 5-HT were significantly greater (vs. vehicle), (2) the insulin-induced enhancement of 5-HT-induced contractions was largely suppressed by inhibitors of the insulin receptor (IR) (GSK1838705A), PI3K (LY294002), and PDK1 (GSK2334470), and (3) the levels of phosphorylated forms of both PDK1 and myosin phosphatase target subunit 1 (MYPT1) were greater upon 5-HT stimulation. In addition, in rat carotid arteries organ-cultured with an activator of PDK1 (PS48), the 5-HT-induced contraction was greater, and this was suppressed by PDK1 inhibition but not PI3K inhibition. In addition, MYPT1 and PDK1 phosphorylation upon 5-HT stimulation was enhanced (vs. vehicle). These results suggest that high insulin levels amplify 5-HT-induced contraction. Moreover, the present results indicated the direct linkage between IR/PI3K/PDK1 activation and 5-HT-induced contraction in rat carotid arteries for the first time.
Collapse
Affiliation(s)
- Shun Watanabe
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Takayuki Matsumoto
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Mirai Oda
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Kosuke Yamada
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Junya Takagi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Kumiko Taguchi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Tsuneo Kobayashi
- Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan.
| |
Collapse
|
21
|
Childress P, Stayrook KR, Alvarez MB, Wang Z, Shao Y, Hernandez-Buquer S, Mack JK, Grese ZR, He Y, Horan D, Pavalko FM, Warden SJ, Robling AG, Yang FC, Allen MR, Krishnan V, Liu Y, Bidwell JP. Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis. Mol Endocrinol 2015; 29:1269-85. [PMID: 26244796 DOI: 10.1210/me.2014-1406] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
PTH is an osteoanabolic for treating osteoporosis but its potency wanes. Disabling the transcription factor nuclear matrix protein 4 (Nmp4) in healthy, ovary-intact mice enhances bone response to PTH and bone morphogenetic protein 2 and protects from unloading-induced osteopenia. These Nmp4(-/-) mice exhibit expanded bone marrow populations of osteoprogenitors and supporting CD8(+) T cells. To determine whether the Nmp4(-/-) phenotype persists in an osteoporosis model we compared PTH response in ovariectomized (ovx) wild-type (WT) and Nmp4(-/-) mice. To identify potential Nmp4 target genes, we performed bioinformatic/pathway profiling on Nmp4 chromatin immunoprecipitation sequencing (ChIP-seq) data. Mice (12 w) were ovx or sham operated 4 weeks before the initiation of PTH therapy. Skeletal phenotype analysis included microcomputed tomography, histomorphometry, serum profiles, fluorescence-activated cell sorting and the growth/mineralization of cultured WT and Nmp4(-/-) bone marrow mesenchymal stem progenitor cells (MSPCs). ChIP-seq data were derived using MC3T3-E1 preosteoblasts, murine embryonic stem cells, and 2 blood cell lines. Ovx Nmp4(-/-) mice exhibited an improved response to PTH coupled with elevated numbers of osteoprogenitors and CD8(+) T cells, but were not protected from ovx-induced bone loss. Cultured Nmp4(-/-) MSPCs displayed enhanced proliferation and accelerated mineralization. ChIP-seq/gene ontology analyses identified target genes likely under Nmp4 control as enriched for negative regulators of biosynthetic processes. Interrogation of mRNA transcripts in nondifferentiating and osteogenic differentiating WT and Nmp4(-/-) MSPCs was performed on 90 Nmp4 target genes and differentiation markers. These data suggest that Nmp4 suppresses bone anabolism, in part, by regulating IGF-binding protein expression. Changes in Nmp4 status may lead to improvements in osteoprogenitor response to therapeutic cues.
Collapse
Affiliation(s)
- Paul Childress
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Keith R Stayrook
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Marta B Alvarez
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Zhiping Wang
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Yu Shao
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Selene Hernandez-Buquer
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Justin K Mack
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Zachary R Grese
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Yongzheng He
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Daniel Horan
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Fredrick M Pavalko
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Stuart J Warden
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Alexander G Robling
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Feng-Chun Yang
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Matthew R Allen
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Venkatesh Krishnan
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Yunlong Liu
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| | - Joseph P Bidwell
- Department of Anatomy and Cell Biology (P.C., S.H.-B., D.H., A.G.R., M.R.A., J.P.B.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Lilly Research Laboratories (K.R.S., J.K.M., Z.R.G., V.K.), Eli Lilly and Company, Indianapolis, Indiana 46202; Orthopaedic Surgery (M.B.A.), Indiana University School of Medicine; Department of Medical and Molecular Genetics (Z.W., Y.S., Y.L., J.P.B.), Indiana University School of Medicine; Center for Computational Biology and Bioinformatics (Z.W., Y.L.), Indiana University School of Medicine; Department of Pediatrics (Y.H., F.-C.Y.), Indiana University School of Medicine; Herman B Wells Center for Pediatric Research (Y.H., F.-C.Y.); Cellular and Integrative Physiology (F.M.P.); Center for Translational Musculoskeletal Research (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University; and Department of Physical Therapy (S.J.W.), School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202
| |
Collapse
|
22
|
Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation. PLoS Pathog 2015; 11:e1005073. [PMID: 26241960 PMCID: PMC4524729 DOI: 10.1371/journal.ppat.1005073] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Accepted: 07/07/2015] [Indexed: 01/05/2023] Open
Abstract
In prion diseases, synapse dysfunction, axon retraction and loss of neuronal polarity precede neuronal death. The mechanisms driving such polarization defects, however, remain unclear. Here, we examined the contribution of RhoA-associated coiled-coil containing kinases (ROCK), key players in neuritogenesis, to prion diseases. We found that overactivation of ROCK signaling occurred in neuronal stem cells infected by pathogenic prions (PrPSc) and impaired the sprouting of neurites. In reconstructed networks of mature neurons, PrPSc-induced ROCK overactivation provoked synapse disconnection and dendrite/axon degeneration. This overactivation of ROCK also disturbed overall neurotransmitter-associated functions. Importantly, we demonstrated that beyond its impact on neuronal polarity ROCK overactivity favored the production of PrPSc through a ROCK-dependent control of 3-phosphoinositide-dependent kinase 1 (PDK1) activity. In non-infectious conditions, ROCK and PDK1 associated within a complex and ROCK phosphorylated PDK1, conferring basal activity to PDK1. In prion-infected neurons, exacerbated ROCK activity increased the pool of PDK1 molecules physically interacting with and phosphorylated by ROCK. ROCK-induced PDK1 overstimulation then canceled the neuroprotective α-cleavage of normal cellular prion protein PrPC by TACE α-secretase, which physiologically precludes PrPSc production. In prion-infected cells, inhibition of ROCK rescued neurite sprouting, preserved neuronal architecture, restored neuronal functions and reduced the amount of PrPSc. In mice challenged with prions, inhibition of ROCK also lowered brain PrPSc accumulation, reduced motor impairment and extended survival. We conclude that ROCK overactivation exerts a double detrimental effect in prion diseases by altering neuronal polarity and triggering PrPSc accumulation. Eventually ROCK emerges as therapeutic target to combat prion diseases. Transmissible Spongiform Encephalopathies (TSEs), commonly named prion diseases, are caused by deposition in the brain of pathogenic prions PrPSc that trigger massive neuronal death. Because of our poor understanding of the mechanisms sustaining prion-induced neurodegeneration, there is to date no effective medicine to combat TSEs. The current study demonstrates that ROCK kinases are overactivated in prion-infected cells and contribute to prion pathogenesis at two levels. First, PrPSc-induced ROCK overactivation affects neuronal polarity with synapse disconnection, axon/dendrite degradation, and disturbs neuronal functions. Second, ROCK overactivity amplifies the production of pathogenic prions. The pharmacological inhibition of ROCK protects diseased neurons from PrPSc toxicity by preserving neuronal architecture and functions and lowering PrPSc level. Inhibition of ROCK in prion-infected mice reduces brain PrPSc levels, improves motor activity and extends lifespan. This study opens up new avenues to design ROCK-based therapeutic strategies to fight TSEs.
Collapse
|
23
|
Upregulation of PDK1 associates with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro. Med Oncol 2014; 31:337. [DOI: 10.1007/s12032-014-0337-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 11/07/2014] [Indexed: 02/08/2023]
|